UNSPSC 51122901: Magnesium gluconate

This classification denotes a nutritional supplement with the molecular formula 2C6H11O7.Mg.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T42NAD2KHC, chemically known as gluconic acid, magnesium salt (2:1), d- but more generally known as magnesium gluconate, which bears US NIH Compound Identifier 19261. European Medicines Agency schedules Magnesium gluconate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14425MIG.

World Health Organization schedules magnesium gluconate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, MAGNESIUM GLUCONATE remains US FDA's Preferred Term for this commodity. Magnesium gluconate bears US NLM identifiers UMLS ID C0126777 and NCI Concept Code C76081. SMILES: C(C(C(C(C(C(=O)[O-])O)O)O)O)O.C(C(C(C(C(C(=O)[O-])O)O)O)O)O.[Mg+2].

UNSPSC 51122901 Magnesium gluconate is a Commodity code that encompasses individual pharmaceutical products supplied to state and local health agencies, emergency medical services, and public health programs. State and local governments procure this and related medications through direct purchase orders to emergency responders, institutional pharmacy benefit programs, and multistate cooperative purchasing alliances. The issuing bodies include municipal fire rescue departments, state health and human services agencies, and regional cooperative purchasing organizations that consolidate demand across multiple jurisdictions. Work under this code involves supplying medications that meet FDA requirements, cGMP certification, Drug Supply Chain Security Act compliance, and strict expiration-date and shelf-life standards, typically with 365-day product warranties and rapid fulfillment windows measured in days to weeks.

Recent activity concentrates in Florida and Minnesota, with secondary engagement from Texas. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications—including epinephrine, labetalol, adenosine, and diltiazem—with a response deadline of April 8, 2026, an estimated contract value of $40,000, and a one-year term with renewal options; the solicitation included a 5 percent SLBE bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, requiring vendors to work through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson) and comply with a 3 percent administrative fee; the contract term runs two years with optional extensions. Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 exploring direct-to-manufacturer prescription fulfillment models outside traditional PBM and GPO channels, signaling future formal procurement activity but carrying no immediate award value or deadline.